for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Oncolytics Biotech, Inc. (USA)

ONCY.OQ

Latest Trade

2.24USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.88

 - 

4.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.24
Open
--
Volume
--
3M AVG Volume
3.92
Today's High
--
Today's Low
--
52 Week High
4.82
52 Week Low
1.88
Shares Out (MIL)
54.96
Market Cap (MIL)
123.99
Forward P/E
-5.16
Dividend (Yield %)
--

Next Event

Q3 2021 Oncolytics Biotech Inc Earnings Call

Latest Developments

More

Oncolytics Biotech Posts Q2 Loss Per Share C$0.13

Oncolytics Biotech Reports 2021 First Quarter Financial Results

Oncolytics Biotech Reports Q4 Loss Per Share C$0.21

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Oncolytics Biotech, Inc. (USA)

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Industry

Biotechnology & Drugs

Contact Info

1167 Kensington Cres Nw Suite 210

Calgary Alberta Canada T2n 1X7

CALGARY, AB

T2R 0C5

Canada

+1.403.6707380

https://www.oncolyticsbiotech.com/

Executive Leadership

Wayne F. Pisano

Independent Chairman of the Board

Matthew C. Coffey

President, Chief Executive Officer, Director

Kirk J. Look

Chief Financial Officer

Andrew De Guttadauro

Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.

Allison Hagerman

Vice President - Product Development

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (CAD)

2018

-1.060

2019

-0.930

2020

-0.560

2021(E)

-0.537
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.28
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.60
LT Debt To Equity (MRQ)
1.10
Return on Investment (TTM)
-70.46
Return on Equity (TTM)
-65.46

Latest News

Latest News

BRIEF-Oncolytics Biotech Announces Phase 2 Trial Evaluating Pelareorep-Anti-Pd-1 Combination Treatment

* ONCOLYTICS BIOTECH® ANNOUNCES INVESTIGATOR SPONSORED PHASE 2 TRIAL EVALUATING PELAREOREP-ANTI-PD-1 COMBINATION TREATMENT IN TRIPLE-NEGATIVE BREAST CANCER Source text for Eikon: Further company coverage:

BRIEF-Oncolytics Biotech Inc Files For Mixed Shelf Of Up To C$150 Million – SEC Filing

* ONCOLYTICS BIOTECH INC FILES FOR MIXED SHELF OF UP TO C$150 MILLION – SEC FILING Source text: (https://bit.ly/3cMfX6c) Further company coverage:

BRIEF-Oncolytics Biotech Presents Clinical Proof-Of-Concept Data In Multiple Myeloma At ASCO Virtual Annual Meeting

* ONCOLYTICS BIOTECH® PRESENTS CLINICAL PROOF-OF-CONCEPT DATA IN MULTIPLE MYELOMA AT THE ASCO VIRTUAL ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Oncolytics Biotech Presents Clinical Proof-Of-Concept Data In Multiple Myeloma At The ASCO Virtual Annual Meeting

* ONCOLYTICS BIOTECH® PRESENTS CLINICAL PROOF-OF-CONCEPT DATA IN MULTIPLE MYELOMA AT THE ASCO VIRTUAL ANNUAL MEETING

BRIEF-Oncolytics Biotech Presents Clinical Data Supporting A Predictive Biomarker Of Pelareorep Response In Breast Cancer At Esmo Breast Cancer Virtual Meeting

* ONCOLYTICS BIOTECH® PRESENTS CLINICAL DATA SUPPORTING A PREDICTIVE BIOMARKER OF PELAREOREP RESPONSE IN BREAST CANCER AT THE ESMO BREAST CANCER VIRTUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Oncolytics Biotech® Announces Publication Of Abstracts At The 2020 ASCO Virtual Annual Meeting

* ONCOLYTICS BIOTECH® ANNOUNCES PUBLICATION OF ABSTRACTS AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY VIRTUAL ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Oncolytics Biotech Reports Quarterly Diluted Loss Per Share Were $0.04

* ONCOLYTICS BIOTECH INC - QTRLY BASIC EARNINGS AND DILUTED LOSS PER SHARE WERE $0.01 AND $0.04

BRIEF-Oncolytics Biotech Announces Publication Of Pelareorep's Clinical Benefit

* ONCOLYTICS BIOTECH® ANNOUNCES PUBLICATION OF PELAREOREP'S CLINICAL BENEFIT AGAINST KRAS MUTATED COLORECTAL CANCER Source text for Eikon: Further company coverage:

BRIEF-Oncolytics Biotech® Announces Favourable Aware-1 Safety Update

* ONCOLYTICS BIOTECH® ANNOUNCES FAVOURABLE AWARE-1 SAFETY UPDATE

BRIEF-Oncolytics Biotech Reports Net Loss For Q4 Was $19.4 Mln

* ONCOLYTICS BIOTECH® REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up